Search results
Results from the WOW.Com Content Network
Regarding these side effects, the label of cariprazine states, "The possibility of lenticular changes or cataracts cannot be excluded at this time." [ 6 ] Because cariprazine and its active metabolites have long half-lives, many healthcare professionals monitor for adverse effects up to several weeks after starting cariprazine.
Methods of prevention include gradually decreasing the dose among those who wish to stop, though it is possible for symptoms to occur with tapering. [2] [6] [4] Treatment may include restarting the medication and slowly decreasing the dose. [2] People may also be switched to the long-acting antidepressant fluoxetine which can then be gradually ...
Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight gain you’ve ...
The stopping of antidepressants for example, can lead to antidepressant discontinuation syndrome. With careful physician attention, however, medication prioritization and discontinuation can decrease costs, simplify prescription regimens, decrease risks of adverse drug events and poly-pharmacy, focus therapies where they are most effective, and ...
Along with sharing tapering tips, members of the groups discuss the risks of prescription cascade, where withdrawal symptoms or the side effects of a psychotropic medication result in further medication, and the risk of neurobiological "kindling" effects where repeated unsuccessful withdrawal attempts yield progressively poor results upon drug ...
The rebound effect, or pharmaceutical rebound phenomenon, is the emergence or re-emergence of symptoms that were either absent or controlled while taking a medication, but appear when that same medication is discontinued, or reduced in dosage.
Vraylar (cariprazine) – atypical antipsychotic used to treat schizophrenia and bipolar mania; W. Wellbutrin IR, SR or XL – an antidepressant of the ...
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...